Toggle light / dark theme

Human Neurons Grew Inside a Living Mouse Brain With Bizarre Results

Support this channel on Patreon to help me make this a full time job: / whatdamath (Unreleased videos, extra footage, DMs, no ads)
Alternatively, PayPal donations can be sent here: http://paypal.me/whatdamath.
Get a Wonderful Person Tee: Amazon: https://amzn.to/3QFIrFX

Hello and welcome! My name is Anton and in this video, we will talk about xenocortication — putting hybrid neurons inside animals.
Links:
https://www.nature.com/articles/s4158…
Previous video: • Lab-Grown Human Brain Cells Can Sense Time…
#xenocortication #neuroscience #neurobiology.

0:00 Xenocortication — what’s that Anton?
1:50 Genetically modified mice and the experiment.
3:10 Older experiment and the challenge.
4:40 New experiment transplanting neurons.
6:00 Human specific neuron formation (VEN)
7:20 Surprise from some of the mice.
8:30 Longterm effects.
10:10 Implications for the medical fields.
11:00 Ethical implications and guidelines.
13:00 Why it’s permitted in mice but not primates.
14:30 Conclusions.

Enjoy and please subscribe.

Bitcoin/Ethereum to spare? Donate them here to help this channel grow!
bc1qnkl3nk0zt7w0xzrgur9pnkcduj7a3xxllcn7d4
or ETH: 0x60f088B10b03115405d313f964BeA93eF0Bd3DbF

The hardware used to record these videos:

Lab-grown tumors reveal immune cells capable of killing small cell lung cancer

Researchers have uncovered a previously overlooked immune cell that can recognize and kill small cell lung cancer, the most aggressive form of the disease globally. Published in Cancer Cell, the WEHI study found patients with higher levels of these cells lived longer, uncovering a hidden immune defense that could be exploited to attack these hard-to-treat tumors.

Researchers also showed existing drugs could be repurposed to boost the cancer-killing activity of these immune cells, opening new opportunities to strengthen current treatments and help more patients benefit from these therapies.

Continuously evolving cells help pancreatic cancer evade treatment and spread

An analysis of nearly half a million cells from dozens of patients’ tumors reveals how cancer cells continuously reshape their genetic makeup over time, enabling them to evade treatment for one of the deadliest forms of cancer.

Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the study focused on pancreatic ductal adenocarcinoma, an often difficult-to-treat disease known to kill nearly 85% of people within five years of diagnosis.

While more than half a dozen genes have been implicated in the complex disease, the analysis of single tumor cells provided new insights into how subpopulations of pancreatic cancer cells reconfigure their DNA within tumors over time.

Revealed: UK’s first operation using a robot that can ‘feel’

But that was not specifically why we were here. It was, instead, because the patient was about to become the first in the UK to have the surgery using a robotic-assisted technology.

Called Force Feedback, it is attached to the da Vinci 5 robotic system, allowing the surgeon for the first time to feel the pressure they are exerting as they push and pull on the patient’s tissue inside their body.

Early results from the US show it’s making surgery more gentle and recovery time faster — and it’s even improving the time the patient is in the operating theatre.

WEHI study reveals a new immune pathway for fighting small cell lung cancer

Researchers have uncovered a previously overlooked immune cell that can recognize and kill small cell lung cancer, the most aggressive form of the disease globally.

Published in Cancer Cell, the WEHI study found patients with higher levels of these cells lived longer, uncovering a hidden immune defence that could be exploited to attack these hard-to-treat tumors.

Researchers also showed existing drugs could be repurposed to boost the cancer-killing activity of these immune cells, opening new opportunities to strengthen current treatments and help more patients benefit from these therapies.

Scientists Investigated People With Insomnia. A Health Risk Pattern Emerged

The researchers identified that across several studies, with more than 1.3 million participants involved, those with insomnia had a 26 percent higher risk of having a stroke. They also found that those people were 28 percent more likely to be hospitalized for any admission reason. Other conditions associated with insomnia included dementia, depression, and suicidal behavior.

When it comes to the association between insomnia and stroke, while research has not yet determined a causal link, Muench said that some theories point toward blood pressure as the potential reason.

“People with insomnia are more likely to develop high blood pressure, but this may be because insomnia and high blood pressure often share the same risk factors, such as stress and lifestyle factors,” she said. “High blood pressure is a risk factor for stroke that people can seek treatment for.”

Jonah Sachs on Winning the Story Wars: Storytelling is our neglected secret weapon

2022, months before ChatGPT turned everyone into a prompt engineer, I spent two hours with Jonah Sachs on a question that now feels urgent: who gets to tell the story?

Jonah has earned the right to an opinion. His film for Amnesty International on blood diamonds was delivered to every member of Congress and helped pass the Clean Diamond Act. The Story of Stuff, which he helped create, reached over 60 million people. He didn’t win those fights with spreadsheets. He won them with #storytelling.

His line has stayed with me ever since: storytelling is the neglected secret weapon we all have.

Here’s what bothers me today. Machines now produce stories by the billion. So is that weapon being handed over to #AI, or is it becoming the one thing that still separates us from the noise?

We went deep on the hero’s journey, the five markers of a great story, what’s broken in our current human story, GPT-3 and two very different Turing Tests, and what Jonah calls the poison and the cure of story. Then he brought up a Buddhist test of suffering that I haven’t been able to shake.

If you work in #marketing, lead people, or care about #socialchange, this one is worth your time. Four years later, it lands harder than it did the day we recorded it.

On the Business Strategies of Platform Biotech Companies

Platform biotech companies face a different strategic landscape relative to single-asset biotechs. Here’s my short educational writeup on the fundamentals of the platform biotech business approach.


Investors may sometimes favor platform biotech companies, though usually only when markets are strong. While opinion tends to swing with the markets, there are certain real advantages to platforms. Particularly, investors find attractive structures with more routes to a very large return outcome, which platforms can offer.

A single-asset company typically will generate a return if it shows a clinical success (often successful phase 2 or even phase 3 clinical trial data) with its sole program and is acquired. By contrast, platform companies are not always killed by a single program failure. So, platforms provide more shots on goal in a sense. That said, if the core platform (e.g. delivery system) fails in humans, the entire company will die [1]. Because of this, it is still critical that the platform company’s first asset program goes well.

Platforms feature routes to preclinical revenue which are much more difficult to achieve for assets. Pharma companies will pay for access to enabling platform technology even when only preclinical data are available. Programs by Dyno Therapeutics (AAVs) [2] and Evox Therapeutics (exosomes) [3] represent examples of the phenomenon. This provides third-party validation and non-dilutive capital before the clinical data, which can support the company during the otherwise most challenging period in a biotech’s lifetime.

Common leukemia mutation derails protein positioning during cell division, study reveals

Experts from the University of Nottingham have discovered how a common genetic mutation disrupts the positioning of a key protein during cell division, revealing a new mechanism behind acute myeloid leukemia and a potential avenue for future treatment.

Acute myeloid leukemia (AML) is an aggressive blood cancer that disrupts the production of healthy blood cells. Around one-third of patients carry a mutation in a gene called NPM1, which causes its protein to accumulate in the wrong part of the cell and plays a key role in driving the disease.

Until now, research has largely focused on how the mutated protein moves between the cell’s nucleus and the surrounding cytoplasm. But a new study, led by Dr. Daniel Booth and Dr. Claire Seedhouse at the University of Nottingham’s School of Medicine, reveals that what happens during cell division itself is also critical.